Physician profile
Daniel X Choi
NPI 1992718092
$744.01
in general payments reported to CMS, 2019-2025
10 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2021: $24.02 · 2022: $57.91 · 2023: $224 · 2024: $108 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amplify Surgical, INC. | $331.49 | 2023-2024 | Dualx and Dulaportal, Dualx and Dualportal, Dualx and Dual Portal |
| Intrinsic Therapeutics | $211.96 | 2025 | Barricaid Acd (Annular Closure Device) |
| Genzyme Corporation | $73.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.44 | 2022 | |
| Covidien LP | $23.10 | 2019 | |
| Procept Biorobotics Corporation | $19.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.78 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.79 | 2019 | |
| Incyte Corporation | $12.69 | 2022 | |
| Amgen INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.